CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: preliminary results of PROCLAIM-CX-072
dc.contributor.author | Naing, A | |
dc.contributor.author | Thistlethwaite, Fiona C | |
dc.contributor.author | Spira, AI | |
dc.contributor.author | Garcia-Corbacho, J | |
dc.contributor.author | Randhawa, M | |
dc.contributor.author | Eskens, F | |
dc.contributor.author | O'Neil, B | |
dc.contributor.author | Lavernia, J | |
dc.contributor.author | Uboha, NV | |
dc.contributor.author | Hamid, O | |
dc.contributor.author | El-Khoueiry, A | |
dc.contributor.author | Benson, BA | |
dc.contributor.author | Garner, W | |
dc.contributor.author | Huels, VJ | |
dc.contributor.author | Arkenau, HT | |
dc.contributor.author | Lorusso, P | |
dc.date.accessioned | 2019-11-19T16:01:07Z | |
dc.date.available | 2019-11-19T16:01:07Z | |
dc.date.issued | 2019 | en |
dc.identifier.citation | Naing A, Thistlethwaite FC, Spira AI, Garcia-Corbacho J, Randhawa M, Eskens F, et al. CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: preliminary results of PROCLAIM-CX-072. J Clin Oncol. 2019;37(15_suppl):2513-. | en |
dc.identifier.doi | 10.1200/JCO.2019.37.15_suppl.2513 | en |
dc.identifier.uri | http://hdl.handle.net/10541/622459 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1200/JCO.2019.37.15_suppl.2513 | en |
dc.title | CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: preliminary results of PROCLAIM-CX-072 | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | MD Anderson Cancer Center, Houston, TX | en |
dc.identifier.journal | Journal of Clinical Oncology | en |